eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. completed its business combination with LifeSci Acquisition 2 Corp, the blank-check company that traded under the ticker LWAC and was sponsored by LifeSci Capital LLC. The SPAC conducted its initial public offering in 2021, targeting the biopharmaceutical sector with a focus on oncology. LifeSci Acquisition 2 was part of the LifeSci family of healthcare-focused SPACs, bringing sector-specific expertise to the transaction. The 8-K filed June 10, 2022, reflects a post-merger disclosure event for the combined company, which develops translation regulatory therapies for cancer. For full filing history, sponsor backgrounds, and deal analytics on LWAC and thousands of other SPACs, sign up for SpacDesk at spacdesk.com.